Logo image
Back
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
Journal article   Open access   Peer reviewed

Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease

Tamas Fulop, Shreyansh Tripathi, Serafim Rodrigues, Mathieu Desroches, Ton Bunt, Arnold Eiser, Francois Bernier, Pascale B Beauregard, Annelise E Barron, Abdelouahed Khalil, …
Neuropsychiatric disease and treatment, v 17, pp 1311-1339
04 May 2021
DOI: https://doi.org/10.2147/NDT.S264910
PMID: 33976546
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.2147/ndt.s264910View
Published, Version of Record (VoR)CC BY-NC V4.0,  Open
url
https://doi.org/10.2147/NDT.S264910View
Published, Version of Record (VoR) Open

Abstract

Alzheimer’s disease antimicrobial immunity brain mild cognitive impairment neuroinflammation Review treatment
Alzheimer’s disease (AD) is the most common form of dementia and aging is the most common risk factor for developing the disease. The etiology of AD is not known but AD may be considered as a clinical syndrome with multiple causal pathways contributing to it. The amyloid cascade hypothesis, claiming that excess production or reduced clearance of amyloid-beta (Aβ) and its aggregation into amyloid plaques, was accepted for a long time as the main cause of AD. However, many studies showed that Aβ is a frequent consequence of many challenges/pathologic processes occurring in the brain for decades. A key factor, sustained by experimental data, is that low-grade infection leading to production and deposition of Aβ, which has antimicrobial activity, precedes the development of clinically apparent AD. This infection is chronic, low grade, largely clinically silent for decades because of a nearly efficient antimicrobial immune response in the brain. A chronic inflammatory state is induced that results in neurodegeneration. Interventions that appear to prevent, retard or mitigate the development of AD also appear to modify the disease. In this review, we conceptualize further that the changes in the brain antimicrobial immune response during aging and especially in AD sufferers serve as a foundation that could lead to improved treatment strategies for preventing or decreasing the progression of AD in a disease-modifying treatment.

Metrics

15 Record Views
17 citations in Web of Science
18 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Clinical Neurology
Psychiatry
Logo image